Yunli Yu
Overview
Explore the profile of Yunli Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Z, Qu Y, Sun Y, Pan J, Zhou T, Yu Y
Pharmaceutics
. 2024 Nov;
16(11).
PMID: 39598572
This study assessed the pharmacokinetic (PK) interactions between clarithromycin (a P-glycoprotein [P-gp] inhibitor) and four direct oral anticoagulants (DOACs) (P-gp substrates) using physiologically based PK (PBPK) models to elucidate the...
2.
Cheng Q, Yu Y, Wan Z, Zhou M, Tang W, Tan W, et al.
Talanta
. 2024 Nov;
283:127178.
PMID: 39520927
It is of great significance to monitor bisphenol A (BPA) in the environment because of its potential environmental and health risks. However, the detection of trace or ultratrace BPA in...
3.
Fan K, Wang Y, Bian J, Sun Y, Dou J, Pan J, et al.
Invest New Drugs
. 2024 Jun;
42(4):418-427.
PMID: 38916794
mTORC1/2 dual inhibitors may be more effective than mTORC1 inhibitor rapamycin. However, their metabolic impacts on colon cancer cells remain unexplored. We conducted a comparative analysis of the anti-proliferative effects...
4.
Qu Y, Yu Y, Pan J, Li H, Cui C, Liu D
Semin Arthritis Rheum
. 2023 Oct;
63:152279.
PMID: 37866004
Objective: Renal safety risk is currently an important factor that hinders the development of uric acid transporter 1 (URAT1) inhibitors. This study aimed to compare the renal safety and uric...
5.
Zhao F, Xiang Z, Han J, Pan J, Qu Y, Fan K, et al.
J Pharm Biomed Anal
. 2023 Oct;
237:115796.
PMID: 37839266
In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency authorization for Paxlovid® as an antiviral treatment for COVID-19. Paxlovid® is composed of two tablets, nirmatrelvir and ritonavir....
6.
Zhou W, Wang M, Yu Y, Wang J, Wu Y, Yang G, et al.
Expert Opin Biol Ther
. 2023 Feb;
23(8):717-725.
PMID: 36843059
Background: HLX02, the first China-manufactured trastuzumab biosimilar, is approved in Europe (EU) and China. This study evaluated bioequivalence between HLX02 and US-approved trastuzumab (US-trastuzumab). Method: In this double-blind, parallel-group, Phase...
7.
Zhu H, Deng X, Feng L, Lian Y, Han X, Guo Z, et al.
CNS Neurosci Ther
. 2022 Apr;
28(7):1072-1080.
PMID: 35429132
Aims: This multicenter, open-label, randomized study (Registration No. ChiCTR-OCH-14004528) aimed to compare the efficacy and effects of oxcarbazepine (OXC) with levetiracetam (LEV) as monotherapies on patient quality of life and...
8.
Qu Y, Su C, Zhao Q, Shi A, Zhao F, Tang L, et al.
Front Pharmacol
. 2022 Mar;
13:837543.
PMID: 35321330
A growing body of evidence suggests that gut microbiota could participate in the progression of depression the microbiota-gut-brain axis. However, the detailed microbial metabolic profile changes in the progression of...
9.
Dong L, Zheng Q, Cheng Y, Zhou M, Wang M, Xu J, et al.
Front Neurosci
. 2022 Mar;
16:803538.
PMID: 35250450
Objective: To characterize the intestinal flora of patients with epilepsy and its correlation with epilepsy. Methods: Patients with ages > 18 years were consecutively enrolled from the outpatient department, Affiliated...
10.
Yu Y, Chu L, Liu C, Huang M, Wang H
Eur Radiol
. 2019 Jul;
29(12):6750-6761.
PMID: 31286187
Objectives: The goal of this study was to investigate alterations of white matter (WM) network in patients with left non-lesional temporal lobe epilepsy (nl-TLE) and right nl-TLE to assess the...